Investigation of antimicrobial and protease-inhibitory activity from cultured cyanobacteria

Pharmaceutical Biology

Volumn 47, Issue 1, 2009, Pages 53-60

  Chlipala, George ^a   Mo, Shunyan ^a   Carcache De Blanco, Esperanza J ^a,b   Ito, Aiko ^a   Bazarek, Stanley ^a   Orjala, Jimmy ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Anthrax; Antimicrobial; Brine shrimp; Cyanobacteria; Protease inhibition; Proteasome; SARS; Tuberculosis

Indexed keywords

ANTIINFECTIVE AGENT; NATURAL PRODUCT; PROTEINASE INHIBITOR;

ANTIMICROBIAL ACTIVITY; ARTEMIA; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL STRAIN; BACTERIUM CULTURE; CYANOBACTERIUM; DRUG ISOLATION; IC 50; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTEINASE INHIBITION; SEVERE ACUTE RESPIRATORY SYNDROME;

ARTEMIA; ARTEMIA SALINA; BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS); CHROOCOCCALES; CYANOBACTERIA; MYCOBACTERIUM TUBERCULOSIS; NOSTOCALES; OSCILLATORIALES; PLEUROCAPSALES; STIGONEMATALES;

EID: 77149132763     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.1080/13880200802415483     Document Type: Article

References (46)

1. Andersen RA, Berges JA, Harrison PJ, Watanabe MM (2005): Recipes for freshwater and seawater media, in: Andersen RA, ed., Algal Culturing Techniques, Burlington, MA, Elsevier Academic Press, pp. 429-538.
2. Andersen RA, Kawachi M (2005): Traditional microalgae isolation techniques, in: Andersen RA, ed., Algal Culturing Techniques, Burlington, MA, Elsevier Academic Press, pp. 83-100.
3. Andersen RA, Morton SL, Sexton JP (1997): Provasoli-Guillard National Center for Culture of Marine Phytoplankton 1997 list of strains. J Phycol 33: S1-75.
4. Athamna A, Athamna M, Abu-Rashed N, Medlej B, Bast DJ, Rubinstein E (2004): Selection of Bacillus anthracis isolates resistant to antibiotics. J Antimicrob Chemother 54: 424-428.
5. Barretto N, Jukneliene D, Ratia K, Chen Z, Mesecar AD, Baker SC (2005): The papain-like protease of severe acute respiratory syndrome Coronavirus has deubiquitinating activity. J Virol 79: 15189-15198.
6. Burger AM, Seth AK (2004): The ubiquitin-mediated protein degradation pathway in cancer: Therapeutic implications. Eur J Cancer 40:2217-2229.
7. Chen L, Gui C, Luo X, Yang Q, Gunther S, Scandella E, Drosten C, Bai D, He X, Ludewig B, Chen J, Luo H, Yang Y, Yang Y, Zou J, Thiel V, Chen K, Shen J, Shen X, Jiang H (2005): Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome Coronavirus and strongly reduces virus replication in vitro. J Virol 79: 7095-7103.
8. Ciechanover A (1994): The ubiquitin-proteasome proteolytic pathway. Cell 79:13-21.
9. Ciechanover A, Iwai K (2004): The Ubiquitin system: From basic mechanisms to the patient bed. IUBMB Life 56: 193-201.
10. Cole ST, Brosch R, Parkhill J, Gamier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S (1998): Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393: 537-544.
11. Collins L, Franzblau SG (1997): Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Ag Chemother 41:1004-1009.
12. Davies-Coleman MT, Dzeha TM, Gray CA, Hess S, Pannell LK, Hendricks DT, Arendse CE (2003): Isolation of homodolastatin 16, a new cyclic depsipeptide from a Kenyan collection of Lyngbya majuscula. J Nat Prod 66: 712-715.
13. El Sayed KA, Bartyzel P, Shen XY, Perry TL, Kjawiony JK, Hamann MT (2000): Marine natural products as antituberculosis agents. Tetrahedron 56: 949-953.
14. Falch BS, Konig GM, Wright AD, Sticher O, Angerhofer CK, Pezzuto JM, Bachmann H (1995): Biological-activities of cyanobacteria - Evaluation of extracts and pure compounds. Planta Med 61: 321-328.
15. Feling RH, Buchanan GO, Mincer TJ, Kauffman CA, Jensen PR, Fenical W (2003): Salinosporamide A: a highly cytotoxic protea-some inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew Chem Int Ed 42: 355-357.
16. Grum-Tokars V, Ratia K, Begaye A, Baker SC, Mesecar AD (2008): Evaluating the 3C-like protease activity of SARS-Coronavirus: Recommendations for standardized assays for drug discovery. Virus Res 133: 63-73.
17. Han B, McPhail KL, Ligresti A, Di Marzo V, Gerwick WH (2003): Semiplenamides A-G, fatty acid amides from a Papua New Guinea collection of the marine cyanobacterium Lyngbya semi-plena. J Nat Prod 66: 1364-1368.
18. Harcourt BH, Jukneliene D, Kanjanahaluethai A, Bechill J, Severson KM, Smith CM, Rota PA, Baker SC (2004): Identification of severe acute respiratory syndrome Coronavirus replicase products and characterization of papain-like protease activity. J Virol 78: 13600-13612.
19. Harvey A (2000): Strategies for discovering drugs from previously unexplored natural products. Drug Discov Today 5: 294-300.
20. Hoshaw RW, Rosowski JR (1973): Methods for microscopic algae, in: JR Stein, eds., Handbook of Phycological Methods: Culture Methods & Growth Measurements, Cambridge, Cambridge University Press, pp. 53-68.
21. Jaki B, Orjala J, Heilmann J, Linden A, Vogler B, Sticher O (2000): Novel extracellular diterpenoids with biological activity from the cyanobacterium Nostoc commune. J Nat Prod 63: 339-343.
22. Kaya K, Mahakhant A, Keovara L, Sano T, Kubo T, Takagi H (2002): Spiroidesin, a novel lipopeptide from the cyanobacterium Anabaena spiroides that inhibits cell growth of the cyanobacterium Microcystis aeruginosa. J Nat Prod 65: 920-921.
23. Khan T, Stauffer JK, Williams R, Hixon JA, Salcedo R, Lincoln E, Back TC, Powell D, Lockett S, Arnold AC, Sayers TJ, Wigginton JM (2006): Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors. J Immunol 176: 6302-6312.
24. King RW, Deshaies RJ, Peters JM, Kirschner MW (1996): How proteolysis drives the cell cycle. Science 274: 1652-1659.
25. Knight J (2001): Delivering death in the mail. Nature 414: 837-838.
26. Komárek J, Anagnostidis K (2005): Cyanoprokaryota 2. Teil: Oscillatoriales. München, Elsevier GmbH, p. 759.
27. Komárek J, Komárková J, Kling H (2003): Filamentous cyanobacteria, in: Wehr JD & Sheath RG, eds., Freshwater Algae of North America, San Diego, CA, Academic Press, pp. 117-196.
28. Komárek J (2003): Coccoid and colonial cyanobacteria, in: Wehr JD & Sheath RG, eds., Freshwater Algae of North America, San Diego, CA, Academic Press, pp. 59-116.
29. Liang PH (2006): Characterization and inhibition of SARS-coronavirus main protease. Curr Top Med Chem 6: 361-376.
30. Macmillan JB, Molinski TF (2005): Majusculoic acid, a brominated cyclopropyl fatty acid from a marine cyanobacterial mat assemblage. J Nat Prod 68: 604-606.
31. Metcalf JS, Lindsay J, Beattie KA, Birmingham S, Saker ML, Torokne AK, Codd GA (2002): Toxicity of cylindrospermopsin to the brine shrimp Artemia salina: Comparisons with protein synthesis inhibitors and microcystins. Toxicon 40: 1115-1120.
32. Meyer BN, Ferrigni NR, Putnam JE, Jacobsen LB, Nichols DE, McLaughlin JL (1982): Brine shrimp: A convenient general bio-assay for active plant constituents. Planta Med 45: 31-34.
33. Mian P, Heilmann J, Burgi HR, Sticher O (2003): Biological screening of terrestrial and freshwater cyanobacteria for antimicrobial activity, brine shrimp lethality, and cytotoxicity. Pharm Biol 4: 243-247.
34. Morens DM, Folkers GK, Fauci AS (2004): The challenge of emerging and re-emerging infectious diseases. Nature 430: 242-249.
35. Nogle LM, Gerwick WH (2002): Somocystinamide A, a novel cytotoxic disulfide dimer from a Fijian marine cyanobacterial mixed assemblage. Org Lett 4: 1095-1098.
36. Nogle LM, Gerwick WH (2003): Diverse secondary metabolites from a Puerto Rican collection of Lyngbya majuscula. J Nat Prod 66: 217-220.
37. Ohta T, Fukuda M (2004): Ubiquitin and breast cancer. Oncogene 23: 2079-2088.
38. Okunade AL, Elvin-Lewis MP, Lewis WH (2004): Natural antimy-cobacterial metabolites: Current status. Phyto chemistry 65: 1017-1032.
39. Ploutno A, Shoshan M, Carmeli S (2002): Three novel protease inhibitors from a natural bloom of the cyanobacterium Microcystis aeruginosa. J Nat Prod 65: 973-978.
40. Quintiliani R Jr, Quintiliani R (2003): Inhalational anthrax and bioter-rorism. Curr Opin Pulm Med 9: 221-226.
41. Schlösser UG (1994): SAG - Sammlung von Algenjulturen at The University of Göttingen. Catalogue of strains 1994. Bot Acta 107: 113-186.
42. Starr RC, Zeikus JA (1993): UTEX - the Culture Collection of Algae at the University-Of-Texas at Austin 1993 List of Cultures. J Phycol 29:1-106.
43. von Elert E, Agrawal MK, Gebauer C, Jaensch H, Bauer U, Zitt A (2004): Protease activity in gut Daphnia magna: Evidence for trypsin and chymotrypsin enzymes. Comp Biochem Phys B Comp Biochem Phys B 137: 287-296.
44. Wetzel RG (2001): The phosphorus cycle, in: Limnology: Lake and River Ecosystems. San Diego, CA, Academic Press, pp. 239-288.
45. Williams PG, Yoshida WY, Moore RE, Paul VJ (2004): Micromide and guamamide: Cytotoxic alkaloids from a species of the marine cyanobacterium Symploca. J Nat Prod 67: 49-53.
46. Yamaki H, Sitachitta N, Sano T, Kaya K (2005): Two new chymotrypsin inhibitors isolated from the cyanobacterium Microcystis aeruginosa NIES-88. J Nat Prod 68: 14-18.